TC Biopharm (Holdings) Plc (TCBPY)

TC Biopharm (Holdings) Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	-	-	3.84	1.98	1.98	3.43
Revenue Growth (YoY)	-	-	94.30%	-	-42.26%	-
Gross Profit	-	-	3.84	1.98	1.98	3.43
Selling, General & Admin	6.4	6.87	8.74	3.11	2.21	3.01
Research & Development	5.57	7.37	7.19	6.16	6.68	8.61
Other Operating Expenses	-0.11	-	-	-	-0.02	-1.56
Operating Expenses	11.86	14.24	15.93	9.27	8.87	10.07
Operating Income	-11.86	-14.24	-12.08	-7.29	-6.89	-6.64
Interest Expense	-0.08	-0.08	-6.75	-3.44	-0.29	-0.28
Interest & Investment Income	-	-	-	0	0	0.02
Currency Exchange Gain (Loss)	-0.08	-0.08	-0.12	-0.08	-	-
Other Non Operating Income (Expenses)	-0.15	8.05	16.06	-4.18	-	-
EBT Excluding Unusual Items	-12.18	-6.35	-2.89	-14.99	-7.18	-6.89
Other Unusual Items	-	-0.65	-0.14	0.01	0.55	-
Pretax Income	-12.18	-7	-3.03	-14.98	-6.63	-6.89
Income Tax Expense	-0.61	-1.09	-1.72	-1.41	-1.17	-0.83
Net Income	-11.57	-5.91	-1.31	-13.58	-5.46	-6.07
Net Income to Common	-11.57	-5.91	-1.31	-13.58	-5.46	-6.07
Free Cash Flow	-8.81	-10.66	-15.53	-5.6	-3.47	-8.76
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-	-314.32%	-368.28%	-348.05%	-193.78%
Profit Margin	-	-	-34.17%	-686.12%	-275.84%	-177.07%
Free Cash Flow Margin	-	-	-404.03%	-283.07%	-175.21%	-255.52%
EBITDA	-11.33	-13.61	-11.32	-6.48	-6.01	-5.92
EBITDA Margin	-	-	-294.48%	-	-	-172.71%
D&A For EBITDA	0.54	0.63	0.76	0.81	0.88	0.72
EBIT	-11.86	-14.24	-12.08	-7.29	-6.89	-6.64
EBIT Margin	-	-	-	-	-	-193.78%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.